Spinal muscular atrophy
MONDO:0001516A motor neuron disease that affect the muscles, and characterized by muscle weakness and atrophy resulting from progressive degeneration and irreversible loss of the anterior horn cells in the spinal cord (i.e., lower motor neurons) and the brain stem nuclei. The severity of the condition; the associated signs and symptoms; and the age at which symptoms develop varies by subtype. In general, people with spinal muscular atrophy (SMA) experience progressive weakness and atrophy of muscles involved in mobility, the ability to sit unassisted, and head control. Breathing and swallowing may also be affected in severe cases. SMA is generally caused by changes (mutations) in the SMN1 gene and is inherited in an autosomal recessive manner. Extra copies of the SMN2 gene modify the severity of SMA. Rare autosomal dominant (caused by mutations in DYNC1H1, BICD2, or VAPB genes) and X-linked (caused by mutations in UBA1) forms of SMA exist. Treatment is based on the signs and symptoms present in each person.
127 clinical trials for this condition and its sub-types, 107 tagged with Spinal muscular atrophy itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Spinal muscular atrophy
-
Proximal spinal muscular atrophy 14 trials · 42 incl. sub-types
6 sub-types
- Spinal muscular atrophy, type 1 17 trials
- Spinal muscular atrophy, type II 14 trials
- Spinal muscular atrophy, type III 13 trials
- Spinal muscular atrophy, type IV 2 trials
- Autosomal dominant childhood-onset proximal spinal muscular atrophy 0 trials Sub-types →
- Lower motor neuron syndrome with late-adult onset 0 trials
-
Bulbospinal muscular atrophy 1 trial
3 sub-types
-
11 sub-types
- Distal hereditary motor neuropathy type 2 0 trials Sub-types →
- Distal hereditary motor neuropathy type 7 0 trials Sub-types →
- Hereditary spastic paraplegia 17 0 trials
- Myopathy, myofibrillar, 13, with rimmed vacuoles 0 trials
- Neuronopathy, distal hereditary motor, autosomal dominant 1 0 trials
- Neuronopathy, distal hereditary motor, autosomal dominant 10 0 trials
- Neuronopathy, distal hereditary motor, autosomal dominant 11 0 trials
- Neuronopathy, distal hereditary motor, autosomal dominant 15 0 trials
- Neuronopathy, distal hereditary motor, autosomal dominant 8 0 trials
- Neuronopathy, distal hereditary motor, type 5 0 trials Sub-types →
- Neuronopathy, distal hereditary motor, type 9 0 trials
-
Spinal muscular atrophy type 0 0 trials
-
Spinal muscular atrophy, segmental 0 trials
Most studied deeper sub-types
-
Gene therapy zolgensma tested in kids with SMA who can sit but not stand
Disease control Stopped earlyThis phase 1 trial tested a gene therapy called AVXS-101 (Zolgensma) in 32 children with spinal muscular atrophy (SMA) who could sit but not stand or walk. The therapy delivers a working SMN gene via a spinal injection to help improve muscle function. The study focused on safety …
Phase 1 • Sponsor: Novartis Gene Therapies • Aim: Disease control
Last updated Jun 27, 2026 08:14 UTC
-
Gut hormone shot aims to strengthen fragile bones in kids with muscle diseases
Knowledge-focused Stopped earlyThis study tested whether two gut hormones, GIP and GLP-2, could reduce bone breakdown in children with spinal muscular atrophy, cerebral palsy, or Duchenne muscular dystrophy who use wheelchairs. Participants received a liquid meal and then either a hormone injection or a placeb…
Sponsor: University of Copenhagen • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:08 UTC